These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The pill: is low estrogen the answer?
    Author: Peck RL.
    Journal: Curr Prescr; 1976 Sep 23; 2(9):19. PubMed ID: 12229573.
    Abstract:
    The benefits of using oral contraceptives with low estrogen content (50 mcg or less) or minipills are discussed. Although no incontrovertible statistical evidence is available, a study by the Royal College of General Practitioners in Great Britain showed that the incidence of thrombosis was decreased by 25% with the use of low estrogen oral contraceptives. Low estrogen oral contraceptives can have relatively estrogenic or progestational effects, depending on the type and ratio of estrogen/progestin components used. Clinical observation of the individual patient using oral contraceptives is important. Patients suffering from estrogen-related side effects (e.g., nausea, fluid retention) can be switched to relatively progestational low-estrogen oral contraceptives, and vice versa. Minipills are not as widely publicized because of a failure rate of 1-4 pregnancies/100 woman-years, a patient dropout rate of up to 50%, and progestin side effects (e.g., amenorrhea, breakthrough bleeding). Ectopic pregnancy seems to be more frequent with minipill use. Minipills are used for estrogen-sensitive women, women with thromboembolic disease, and breast-feeding women. The minipill is less likely to endanger the life of the mother or fetus in the case of pregnancy than is IUD use.
    [Abstract] [Full Text] [Related] [New Search]